TOP TEN perturbations for NP_733832 (Homo sapiens)

Organism: Homo sapiens
Gene: NP_733832
Selected probe(set): 204346_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NP_733832 (204346_s_at) across 6593 perturbations tested by GENEVESTIGATOR:

cicloheximide study 1 / vehicle (DMSO) treated MCF-7 cell sample

Relative Expression (log2-ratio):2.3169718
Number of Samples:4 / 4
Experimental cicloheximide study 1
MCF7 breast cancer cells were treated for 1h with cicloheximide (10 ug/ml) before vehicle treatment (0.1% ethanol) for 24h. ATC code:---
Control vehicle (DMSO) treated MCF-7 cell sample
MCF7 breast cancer cells treated with vehicle DMSO (0.1%) for 1h and subsequently with vehicle (0.1% ethanol) for 24h.

estradiol; cicloheximide study 1 / vehicle (DMSO) treated MCF-7 cell sample

Relative Expression (log2-ratio):2.150178
Number of Samples:4 / 4
Experimental estradiol; cicloheximide study 1
MCF7 breast cancer cells were treated with cicloheximide (10 ug/ml) for 1 hour before hormonal treatment with 17{beta}-estradiol (E2, 25 nM) for 24 hours. ATC code:
Control vehicle (DMSO) treated MCF-7 cell sample
MCF7 breast cancer cells treated with vehicle DMSO (0.1%) for 1h and subsequently with vehicle (0.1% ethanol) for 24h.

ARC study 1 / untreated MCF-7 cell sample

Relative Expression (log2-ratio):1.8804455
Number of Samples:2 / 2
Experimental ARC study 1
MCF7 cells treated with 2uM ARC (4-amino-6-hydrazino-7-beta-d-ribofuranosyl-7H-pyrrolo-(2, 3-d)-pyrimidine-5-carboxamide, NSC 188491) for 24 hours. ATC code:---
Control untreated MCF-7 cell sample
MCF-7 cells untreated.

wound healing study 2 (ex vivo; AG1478) / normal skin tissue (ex vivo)

Relative Expression (log2-ratio):1.8671932
Number of Samples:3 / 3
Experimental wound healing study 2 (ex vivo; AG1478)
Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing AG1478 for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 10 micromolar AG1478 (dissolved in DMSO). The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin. AG1478 is EGFR kinase inhibitor. ATC code:---
Control normal skin tissue (ex vivo)
Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection.

precursor-B-ALL study 7 (PDX; long-term; >10wk) / precursor-B-ALL study 7 (late relapse; >24m)

Relative Expression (log2-ratio):-1.8104715
Number of Samples:7 / 8
Experimental precursor-B-ALL study 7 (PDX; long-term; >10wk)
Leukemia cell samples isolated from spleen of patient derived xenografts (PDX) of precursor B-cell acute lymphoblastic leukemia generated in NOD/SCID mice with time to manifestation of leukemia (TTL) more than 10 weeks (long-term). Cell suspensions containing more than 90% leukemia cells as estimated by flow cytometry were prepared from infiltrated spleens of leukemia bearing mice. Briefly, unconditioned NOD/SCID (NOD.CB17-Prkdcscid/NCrCrl) mice with a median age of 10 weeks were transplanted by injection of patient leukemia cells, which were isolated from bone marrow or peripheral blood of pediatric patients with precursor BCP-ALL, into the lateral tail vein. Upon clear evidence for leukemia related morbidity, mice were killed and autopsy was performed. Leukemia was confirmed detecting leukemia cells in bone marrow, spleen and peripheral blood. Time to leukemia (TTL) was determined as weeks from transplant to clinical leukemia manifestation. Donor characteristics: 3 females and 9 males; 1-9 years old; good response to prednison; no fusion gene; remision at day 33; non-high risk group; late relapse group (relapse after 24 months from diagnosis).
Control precursor-B-ALL study 7 (late relapse; >24m)
Leukemia cell samples isolated from bone marrow of pediatric patients with precursor B-cell acute lymphoblastic leukemia (B-ALL) with relapse after 24 months from diagnosis (late relapse). White blood cells were isolated through Ficoll-Hypaque density gradient centrifugation. All diagnostic leukemia samples were obtained before treatment from pediatric de novo B cell precursor ALL patients (BCP-ALL). Samples obtained from studies registred under NCT00430118 and NCT00613457.

deferoxamine study 5 / untreated U251 astroglioma cell sample

Relative Expression (log2-ratio):1.7722349
Number of Samples:3 / 2
Experimental deferoxamine study 5
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:
Control untreated U251 astroglioma cell sample
Untreated human astroglioma (U251) cells not stimulated with deferoxamine (DFO).

hCMV study 1 (CD69+) / uninfected CD4 T-LGL sample (diseased)

Relative Expression (log2-ratio):-1.7502899
Number of Samples:4 / 3
Experimental hCMV study 1 (CD69+)
CD69+ human cytomegalovirus (hCMV)-stimulated monoclonal CD4+ T-large granular lymphocytes (T-LGL) from peripheral blood of patients with monoclonal T-cell receptor (TCR)-alphabeta(+)/CD4(+) T-large granular lymphocyte (LGL) lymphocytosis.
Control uninfected CD4 T-LGL sample (diseased)
Unstimulated monoclonal CD4+ T-large granular lymphocytes (T-LGL) from peripheral blood of patients with monoclonal T-cell receptor (TCR)-alphabeta(+)/CD4(+) T-large granular lymphocyte (LGL) lymphocytosis.

glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):1.6888332
Number of Samples:2 / 3
Experimental glioma study 17 (anaplastic astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

HIF-1a depletion study 1 (siRNA) / deferoxamine study 5

Relative Expression (log2-ratio):-1.6807747
Number of Samples:3 / 3
Experimental HIF-1a depletion study 1 (siRNA)
siRNA against HIF-1a treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h).
Control deferoxamine study 5
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:

pancreatic islet study 3 (re-differentiated; NIH) / normal pancreatic islet sample

Relative Expression (log2-ratio):1.6400366
Number of Samples:4 / 7
Experimental pancreatic islet study 3 (re-differentiated; NIH)
Pancreatic islet cells were expanded for 10 weeks and re-differentiated for 1 week according to National Institutes of Health (NIH) protocol. Re-differentiation phase: Expanded cells were cultured for 1 week in serum-free CMRL-1066 medium supplemented with insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml).
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.